Shared on07 Aug 25Fair value Increased 7.58%
A lower future P/E indicates improved earnings expectations, while a higher discount rate suggests increased perceived risk, yet analysts have still raised Rhythm Pharmaceuticals’ fair value to $110.71 per share. What's in the News Rhythm Pharmaceuticals presented new clinical data on bivamelagon (oral MC4R agonist) and setmelanotide (lead asset) in patients with acquired hypothalamic obesity at ENDO 2025; setmelanotide remains FDA approved for syndromic monogenic obesity due to defined genetic deficiencies.